Jose F Leis

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)
    Jose F Leis
    Oregon Health and Sciences University, Adult Bone Marrow Transplant Program, Portland, OR 97201, USA
    Leuk Lymphoma 45:695-8. 2004
  2. ncbi request reprint Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis
    Jose F Leis
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Haematologica 89:ECR30. 2004
  3. doi request reprint Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma
    Tarunpreet Bains
    Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Leuk Lymphoma 55:583-7. 2014
  4. ncbi request reprint Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay
    Yanping Zhong
    Department of Pathology, Oregon Heath and Science University, Portland, Oregon 97201 3098, USA
    Cytometry B Clin Cytom 72:189-95. 2007
  5. pmc Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Christoph Kahl
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:2744-8. 2007

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571)
    Jose F Leis
    Oregon Health and Sciences University, Adult Bone Marrow Transplant Program, Portland, OR 97201, USA
    Leuk Lymphoma 45:695-8. 2004
    ..These results suggest that IM may not penetrate the intact blood/brain barrier and its implications are discussed...
  2. ncbi request reprint Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis
    Jose F Leis
    Center for Hematologic Malignancies, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Haematologica 89:ECR30. 2004
    ..No electrolyte abnormalities consistent with tumor lysis syndrome were observed. IM may be an effective single agent therapy for pulmonary leukostasis in patients with CML blast crisis who are at the risk for tumor lysis...
  3. doi request reprint Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma
    Tarunpreet Bains
    Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    Leuk Lymphoma 55:583-7. 2014
    ..There were more cases of severe mucositis but fewer episodes of bacteremia with BuMelTt. Our results suggest that BuMelTt may be a superior conditioning regimen for autoSCT in Hodgkin lymphoma...
  4. ncbi request reprint Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay
    Yanping Zhong
    Department of Pathology, Oregon Heath and Science University, Portland, Oregon 97201 3098, USA
    Cytometry B Clin Cytom 72:189-95. 2007
    ..It would be highly desirable to develop a personalized therapeutic strategy for selection of appropriate drugs or regimens based on the drug sensitivity profiles of leukemic cells from individuals...
  5. pmc Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Christoph Kahl
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:2744-8. 2007
    ..The latter might benefit from cytoreductive treatment before HCT...